According to a press release, Zynnon AG has verified in a study that its model for the diagnosis and prediction of viral respiratory infections functions as desired. The biotech company, which was founded in 2019 in Schindellegi in the canton of Schwyz, carried out the study at Hospital Nanterre in Paris, for which 31 patients were enrolled.
To model virus transmission via the respiratory tract, real-time data was collected in hospital settings and evaluated with the help of Artificial Intelligence. The aim here was to develop a solution with the capacity to predict transmission risk, which would aid the implementation of preventive or curative measures in hospitals and care facilities.
The clinical trial at Hospital Nanterre, which has now been completed, was able to practically verify the research findings for the first time. According to the information, Zynnon’s technology was able to successfully distinguish between infected and non-infected patients with precisions, in turn making it possible to diagnose viral respiratory diseases quickly and accurately. By precisely identifying the causes of infection, the use of antibiotics should be “significantly reduced”.
“The success of Zynnon’s clinical feasibility study is a turning point for the diagnosis of respiratory infections”, as study leader Professor Elisabeth Aslangul comments in the press release, before adding: “The ability to quickly and accurately detect respiratory infections has the potential to revolutionize patient care and contribute to effective treatment strategies”. ce/ww
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space